重庆康华瑞明科技股份有限公司创始于 2012年改制为股份有限公司，是中国研发和制造眼科仪器的领导者，拥有约350名员工队伍，占地30亩。此外，康华瑞明已通过ISO9001：2000和ISO13485：2003质量管理体系和CE认证，眼底照相机和投射视野计获得了FDA认证。
拥有光学，机械，电子，精细工艺，还有微电子，聚合物，激光，超声波等高科技研发能力，而且全面实施CAD，CAM，CAPP，PDM数字化设计和数字化制造NC数字化管理和ERP。此外，康华瑞明也在裂隙灯，数字裂隙灯，便携式裂隙灯，投射视野计，A/B超，眼底照相机，眼底荧光造影，干眼诊断等方面取得了优异的成绩。
Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products.
The Company’s main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, chinese patent medicine(Keluoxin capsules,S huganjieyu capsules, Danshu capsules and Yiqing capsules) ,western medicine (venlafaxine hydrochloride capsules, mosapride citrate tablets, dexSuzbotitple iHcelreone tablets,etc), and biomedical equipment. The Company distributes its products in domestic market. In 2019, Chengdu Kanghong Pharmaceutical Group Co., Ltd is rated one of the top 500 private enterprise in China with a market value of 35 billion.